Find trials
Consejos para buscar

Registry of Patients Treated With Systemic Mold-Active Triazoles

Overview

Información sobre este estudio

The purpose of this study is to describe representative real-world patterns of care for the management of invasive fungal infections (IFIs), including invasive mold infection (IMI). Specifically, the study goals are to examine real world patient characteristics and treatment patterns, associated healthcare resource utilization, and outcomes associated with use of mold-active triazoles (MATs) to treat invasive fungal infections (IFIs).

Elegibilidad para la participación

Los requisitos de elegibilidad de los participantes incluyen la edad, el sexo, el tipo y el estadio de la enfermedad, y los problemas de salud o tratamientos previos. Las pautas difieren de un estudio a otro e identifican quiénes pueden o no pueden participar. No hay garantía de que cada persona elegible que desee participar en un ensayo se inscribirá. Comunícate con el equipo del estudio para analizar la elegibilidad del estudio y la posible participación.

Inclusion Criteria:

For enrollment, patients must meet both of the following inclusion criteria:

  • Taking one of the following target drugs at the time of enrollment: ISAV, VORI, POSA.
  • For patients ≥ 18 years old, patient or legal representative has provided the appropriate consent and/or release, consistent with local requirements, to access medical records given consent and/or data release if required by institutional policy, state and/or governmental laws, including access to all relevant clinical and medication data, and the storage and analysis of this data. For patients < 18 years old, informed consent must be obtained from the patient’s parent(s) or legal guardian(s) and patient assent (where appropriate) must be given.

Exclusion Criteria:

Patients meeting any of the following criteria must be excluded:

  • Currently enrolled in any clinical trial with an investigational antifungal agent.  Individuals who subsequently enroll in an investigational antifungal study will be discontinued and data collected up to the time of investigational product will be evaluable.
  • Patients who died before entering the study.
  • Patients who previously participated in this registry.

 

Sedes participantes de Mayo Clinic

Los estatus de los estudios cambian con frecuencia. Comunícate con el equipo del estudio para obtener la información más actualizada acerca de la posibilidad de participar.

Sede de Mayo Clinic Estatus

Rochester, Minn.

Investigador principal de Mayo Clinic

Jason Barreto, Pharm.D.

Cerrado para la inscripción

More information

Publicaciones

Publications are currently not available

Otros temas en investigación

.
CLS-20316213

Mayo Clinic Footer